Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA.
Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA.
Cell. 2022 Dec 8;185(25):4801-4810.e13. doi: 10.1016/j.cell.2022.10.024. Epub 2022 Nov 22.
Drug-drug interaction of the antiviral sofosbuvir and the antiarrhythmics amiodarone has been reported to cause fatal heartbeat slowing. Sofosbuvir and its analog, MNI-1, were reported to potentiate the inhibition of cardiomyocyte calcium handling by amiodarone, which functions as a multi-channel antagonist, and implicate its inhibitory effect on L-type Ca channels, but the molecular mechanism has remained unclear. Here we present systematic cryo-EM structural analysis of Ca1.1 and Ca1.3 treated with amiodarone or sofosbuvir alone, or sofosbuvir/MNI-1 combined with amiodarone. Whereas amiodarone alone occupies the dihydropyridine binding site, sofosbuvir is not found in the channel when applied on its own. In the presence of amiodarone, sofosbuvir/MNI-1 is anchored in the central cavity of the pore domain through specific interaction with amiodarone and directly obstructs the ion permeation path. Our study reveals the molecular basis for the physical, pharmacodynamic interaction of two drugs on the scaffold of Ca channels.
抗病毒药物索非布韦与抗心律失常药物胺碘酮的药物相互作用已被报道可导致致命的心跳减缓。据报道,索非布韦及其类似物 MNI-1 可增强胺碘酮对心肌细胞钙处理的抑制作用,胺碘酮作为多通道拮抗剂发挥作用,并暗示其对 L 型钙通道的抑制作用,但分子机制尚不清楚。在这里,我们对用胺碘酮或索非布韦单独处理或用索非布韦/MNI-1 与胺碘酮联合处理的 Ca1.1 和 Ca1.3 进行了系统的冷冻电镜结构分析。虽然胺碘酮单独占据二氢吡啶结合位点,但当单独使用索非布韦时,通道中未发现索非布韦。在胺碘酮存在的情况下,索非布韦/MNI-1 通过与胺碘酮的特异性相互作用锚定在孔域的中央腔中,并直接阻塞离子渗透途径。我们的研究揭示了两种药物在钙通道支架上的物理、药效相互作用的分子基础。